When an FDA advisory committee votes “yes,” the headlines often read like the decision is made. It isn’t. Here is what actually has to happen next — using the July 2026 peptide vote as the live example.

Step 1: the committee advises

An advisory committee is exactly that — advisory. It studies the evidence and makes a recommendation. It has no power to change a rule, and the FDA is not required to agree. In July 2026, the peptide panel even voted against the FDA’s own scientists.

Step 2: the FDA decides whether to act

The agency weighs the recommendation alongside its own review and decides whether to move forward. It can follow the committee, modify the scope, or decline — which the FDA has signaled it may do for BPC-157.

Step 3: formal rulemaking

If the FDA does move, it publishes a proposed rule, opens a public comment period, reviews the comments, and then issues a final rule with an effective date. Only then does anything actually change.

“Recommended” is the first step of many. “Available and legal” is the last one — and they can be a long way apart.

How long, and how certain?

This can take months to years, and it can stall or change along the way. That is why we treat an advisory vote as a milestone to watch, not a finish line — and why “recommended” should never be read as “legal to buy and use.”